Valeant puts dealmaking on hold to focus on the bottom line
In partnership with activist investor Bill Ackman, the company made a hostile bid to purchase Botox-maker Allergan. Valeant Pharmaceuticals is putting its acquisition growth strategy on hold in favor of reducing debt and boosting its stock price, according to Reuters. Since 2008, Valeant has spent about $19 billion on 40 acquisitions. Now, the company will [...]